166 related articles for article (PubMed ID: 38522013)
1. Epidermal growth factor receptor inhibition potentiates chemotherapeutics-mediated sensitization of metastatic breast cancer stem cells.
Kar T; Dugam P; Shivhare S; Shetty SR; Choudhury S; Sen D; Deb B; Majumdar S; Debnath S; Das A
Cancer Rep (Hoboken); 2024 Mar; 7(3):e2049. PubMed ID: 38522013
[TBL] [Abstract][Full Text] [Related]
2. Inhibiting epidermal growth factor receptor signalling potentiates mesenchymal-epithelial transition of breast cancer stem cells and their responsiveness to anticancer drugs.
Manupati K; Dhoke NR; Debnath T; Yeeravalli R; Guguloth K; Saeidpour S; De UC; Debnath S; Das A
FEBS J; 2017 Jun; 284(12):1830-1854. PubMed ID: 28398698
[TBL] [Abstract][Full Text] [Related]
3. Excellent effects and possible mechanisms of action of a new antibody-drug conjugate against EGFR-positive triple-negative breast cancer.
Zhou DD; Bai WQ; Zhai XT; Sun LP; Zhen YS; Li ZR; Miao QF
Mil Med Res; 2021 Dec; 8(1):63. PubMed ID: 34879870
[TBL] [Abstract][Full Text] [Related]
4. Suppression of TNBC metastasis by doxazosin, a novel dual inhibitor of c-MET/EGFR.
Kim S; Park JM; Park S; Jung E; Ko D; Park M; Seo J; Nam KD; Kang YK; Lee K; Farrand L; Kim YJ; Kim JY; Seo JH
J Exp Clin Cancer Res; 2023 Nov; 42(1):292. PubMed ID: 37924112
[TBL] [Abstract][Full Text] [Related]
5. EGFR inhibition blocks cancer stem cell clustering and lung metastasis of triple negative breast cancer.
Liu X; Adorno-Cruz V; Chang YF; Jia Y; Kawaguchi M; Dashzeveg NK; Taftaf R; Ramos EK; Schuster EJ; El-Shennawy L; Patel D; Zhang Y; Cristofanilli M; Liu H
Theranostics; 2021; 11(13):6632-6643. PubMed ID: 33995681
[TBL] [Abstract][Full Text] [Related]
6. Combination Treatment with EGFR Inhibitor and Doxorubicin Synergistically Inhibits Proliferation of MCF-7 Cells and MDA-MB-231 Triple-Negative Breast Cancer Cells In Vitro.
Abrahams B; Gerber A; Hiss DC
Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474312
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of Cetuximab in combination with Ixabepilone on triple negative breast cancer stem cells.
Tanei T; Choi DS; Rodriguez AA; Liang DH; Dobrolecki L; Ghosh M; Landis MD; Chang JC
Breast Cancer Res; 2016 Jan; 18(1):6. PubMed ID: 26757880
[TBL] [Abstract][Full Text] [Related]
8. GSK3β regulates epithelial-mesenchymal transition and cancer stem cell properties in triple-negative breast cancer.
Vijay GV; Zhao N; Den Hollander P; Toneff MJ; Joseph R; Pietila M; Taube JH; Sarkar TR; Ramirez-Pena E; Werden SJ; Shariati M; Gao R; Sobieski M; Stephan CC; Sphyris N; Miura N; Davies P; Chang JT; Soundararajan R; Rosen JM; Mani SA
Breast Cancer Res; 2019 Mar; 21(1):37. PubMed ID: 30845991
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of Vasculogenic Mimicry and Angiogenesis by an Anti-EGFR IgG1-Human Endostatin-P125A Fusion Protein Reduces Triple Negative Breast Cancer Metastases.
Shin SU; Cho HM; Das R; Gil-Henn H; Ramakrishnan S; Al Bayati A; Carroll SF; Zhang Y; Sankar AP; Elledge C; Pimentel A; Blonska M; Rosenblatt JD
Cells; 2021 Oct; 10(11):. PubMed ID: 34831127
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Cdk2 kinase activity selectively targets the CD44⁺/CD24⁻/Low stem-like subpopulation and restores chemosensitivity of SUM149PT triple-negative breast cancer cells.
Opyrchal M; Salisbury JL; Iankov I; Goetz MP; McCubrey J; Gambino MW; Malatino L; Puccia G; Ingle JN; Galanis E; D'Assoro AB
Int J Oncol; 2014 Sep; 45(3):1193-9. PubMed ID: 24970653
[TBL] [Abstract][Full Text] [Related]
11. Co-inhibition of mTORC1, HDAC and ESR1α retards the growth of triple-negative breast cancer and suppresses cancer stem cells.
Sulaiman A; McGarry S; Lam KM; El-Sahli S; Chambers J; Kaczmarek S; Li L; Addison C; Dimitroulakos J; Arnaout A; Nessim C; Yao Z; Ji G; Song H; Liu S; Xie Y; Gadde S; Li X; Wang L
Cell Death Dis; 2018 Jul; 9(8):815. PubMed ID: 30050079
[TBL] [Abstract][Full Text] [Related]
12. Oligo-Fucoidan supplementation enhances the effect of Olaparib on preventing metastasis and recurrence of triple-negative breast cancer in mice.
Chen LM; Yang PP; Al Haq AT; Hwang PA; Lai YC; Weng YS; Chen MA; Hsu HL
J Biomed Sci; 2022 Sep; 29(1):70. PubMed ID: 36109724
[TBL] [Abstract][Full Text] [Related]
13. A kinase inhibitor screen identifies a dual cdc7/CDK9 inhibitor to sensitise triple-negative breast cancer to EGFR-targeted therapy.
McLaughlin RP; He J; van der Noord VE; Redel J; Foekens JA; Martens JWM; Smid M; Zhang Y; van de Water B
Breast Cancer Res; 2019 Jul; 21(1):77. PubMed ID: 31262335
[TBL] [Abstract][Full Text] [Related]
14. Eradication of cancer stem cells in triple negative breast cancer using doxorubicin/pluronic polymeric micelles.
Zhao Y; Alakhova DY; Zhao X; Band V; Batrakova EV; Kabanov AV
Nanomedicine; 2020 Feb; 24():102124. PubMed ID: 31756533
[TBL] [Abstract][Full Text] [Related]
15. Glutathione S-transferase omega 1 inhibition activates JNK-mediated apoptotic response in breast cancer stem cells.
Manupati K; Debnath S; Goswami K; Bhoj PS; Chandak HS; Bahekar SP; Das A
FEBS J; 2019 Jun; 286(11):2167-2192. PubMed ID: 30873742
[TBL] [Abstract][Full Text] [Related]
16. ZEB1 potentiates chemoresistance in breast cancer stem cells by evading apoptosis.
Shivhare S; Choudhury S; Singh D; Das A
Biochim Biophys Acta Mol Cell Res; 2023 Oct; 1870(7):119528. PubMed ID: 37356459
[TBL] [Abstract][Full Text] [Related]
17. TWIST1-mediated transcriptional activation of PDGFRβ in breast cancer stem cells promotes tumorigenesis and metastasis.
Yeeravalli R; Kaushik K; Das A
Biochim Biophys Acta Mol Basis Dis; 2021 Jul; 1867(7):166141. PubMed ID: 33845139
[TBL] [Abstract][Full Text] [Related]
18. Doxorubicin-Resistant TNBC Cells Exhibit Rapid Growth with Cancer Stem Cell-like Properties and EMT Phenotype, Which Can Be Transferred to Parental Cells through Autocrine Signaling.
Paramanantham A; Jung EJ; Kim HJ; Jeong BK; Jung JM; Kim GS; Chan HS; Lee WS
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830320
[TBL] [Abstract][Full Text] [Related]
19. Stat3/Oct-4/c-Myc signal circuit for regulating stemness-mediated doxorubicin resistance of triple-negative breast cancer cells and inhibitory effects of WP1066.
Cheng CC; Shi LH; Wang XJ; Wang SX; Wan XQ; Liu SR; Wang YF; Lu Z; Wang LH; Ding Y
Int J Oncol; 2018 Jul; 53(1):339-348. PubMed ID: 29750424
[TBL] [Abstract][Full Text] [Related]
20. Ginsenoside 20(S)-protopanaxadiol inhibits triple-negative breast cancer metastasis in vivo by targeting EGFR-mediated MAPK pathway.
Peng B; He R; Xu Q; Yang Y; Hu Q; Hou H; Liu X; Li J
Pharmacol Res; 2019 Apr; 142():1-13. PubMed ID: 30735802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
